Endometriosis Treatment Market Size Projected to Reach $5.73 billion by 2034 | 12.37%

According to Straits Research, the global endometriosis treatment market size was estimated at $2.01 billion in 2025 and is projected to reach $5.73 billion by 2034, registering a CAGR of 12.37% during the forecast period 2026–2034.

Market Dynamics

The growth of the global endometriosis treatment market is driven by the rising prevalence of endometriosis among women of reproductive age, increased awareness regarding early diagnosis and management, and advancements in hormonal and non-hormonal therapeutic options that offer better symptom control and improved quality of life. However, the market growth is restrained by the high cost of advanced treatments, the limited efficacy of existing drugs in severe cases, and potential side effects associated with long-term hormonal therapy, which reduce patient adherence. On the other hand, significant opportunities lie in the development of novel non-hormonal drugs with fewer side effects, increasing research on personalized and regenerative treatment approaches, and expanding healthcare access in emerging markets, which are expected to drive future growth in the endometriosis treatment landscape.

Market Segments

1. By Drug Type (2026-2034)
   1. Hormonal Therapy
      1. Gonadotropin-Releasing Hormone (GnRH) Agonists
      2. Oral Contraceptives
      3. Progestins
      4. Danazol
   2. Non-Hormonal Therapy
      1. NSAIDs
      2. Analgesics
2. By Route of Administration (2026-2034)
   1. Oral
   2. Injectables
   3. Nasal
   4. Others (e.g., implants, transdermal patches)
3. By Distribution Channel (2026-2034)
   1. Hospital pharmacy
   2. Retail pharmacy
   3. Others